Linked Life Data

18841401

Source:http://linkedlifedata.com/resource/pubmed/id/18841401

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2009-4-1
pubmed:abstractText
The objective was to evaluate the effectiveness and safety of simplification from tenofovir-lamivudine (TDF-3TC) to Truvada (TVD) in virologically suppressed HIV patients. We carried out an open-label, multicentre, non-controlled study of HIV patients on a stable regimen including TDF-3TC who switched from TDF-3TC to TVD. Viral load responses at 24 and 48 weeks were evaluated. Changes in the calculated glomerular filtration rates (cGFR; Cockcroft-Gault equation) were analysed at baseline and at 24 and 48 weeks. Patients with drug-related nephrotoxicity (cGFR < 60 mL/min at 48 weeks or interruption of TVD because of renal toxicity) were analysed in detail. Two hundred and ninety-five patients with a mean time on TDF-3TC of 19.9 months (range 8.8-29.8) were enrolled. The third drug was a non-nucleoside reverse transcriptase inhibitor, which was administered to 187 patients (76.4% efavirenz) and a protease inhibitor was administered to 108 (43.5% lopinavir/ritonavir). At 48 weeks, 85.7% of the patients were still taking the same regimen, all with an undetectable viral load. The cGFR (mL/min) decreased from baseline (111 [89-130]) to 48 weeks (105 [84-121]); p < 0.0001. The percentage of patients with a cGFR <60 mL/min at 48 weeks was 3.5. Six patients ceased TVD because of drug-related nephrotoxicity. The only factors associated with nephrotoxicity were age, baseline weight and cGFR. Simplification from TDF-3TC to TVD was associated with a decrease in cGFR, with a low prevalence of nephrotoxicity at 48 weeks.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
1435-4373
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
28
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
399-402
pubmed:meshHeading
pubmed-meshheading:18841401-Adenine, pubmed-meshheading:18841401-Adult, pubmed-meshheading:18841401-Anti-HIV Agents, pubmed-meshheading:18841401-Antiretroviral Therapy, Highly Active, pubmed-meshheading:18841401-CD4 Lymphocyte Count, pubmed-meshheading:18841401-Central Nervous System, pubmed-meshheading:18841401-Cohort Studies, pubmed-meshheading:18841401-Creatinine, pubmed-meshheading:18841401-Deoxycytidine, pubmed-meshheading:18841401-Drug Combinations, pubmed-meshheading:18841401-Female, pubmed-meshheading:18841401-HIV Infections, pubmed-meshheading:18841401-HIV-1, pubmed-meshheading:18841401-Humans, pubmed-meshheading:18841401-Kidney, pubmed-meshheading:18841401-Lamivudine, pubmed-meshheading:18841401-Male, pubmed-meshheading:18841401-Metabolic Clearance Rate, pubmed-meshheading:18841401-Middle Aged, pubmed-meshheading:18841401-Organophosphorus Compounds, pubmed-meshheading:18841401-Phosphonic Acids, pubmed-meshheading:18841401-RNA, Viral, pubmed-meshheading:18841401-Retrospective Studies, pubmed-meshheading:18841401-Risk Factors, pubmed-meshheading:18841401-Viral Load
pubmed:year
2009
pubmed:articleTitle
Effectiveness and safety of simplification from tenofovir-lamivudine (TDF-3TC) to tenofovir-emtricitabine (TDF-FTC) co-formulation (Truvada) in virologically suppressed HIV-infected patients on HAART.
pubmed:affiliation
Hosp. Virgen de la Victoria, Campus Teatinus s/n, Málaga, Spain.
pubmed:publicationType
Journal Article, Multicenter Study